Trial Profile
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Fibroma
- Focus Therapeutic Use
- 06 Jun 2023 Status changed from active, no longer recruiting to completed.
- 20 Dec 2018 Results published in the New England Journal of Medicine
- 05 Jun 2018 Results (n=87) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.